Loading...

Stephen Stahl

TitleAdjunct Professor
InstitutionUniversity of California San Diego
DepartmentPsychiatry
Address9500 Gilman Drive #9116A
La Jolla CA 92093
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    HUMAN 5HT RECEPTOR REGULATION BY ANTIDEPRESSANTS
    NIH/NIMH R01MH045787Sep 1, 1991 - Jan 31, 1995
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Stahl SM. New hope for Alzheimer's dementia as prospects for disease modification fade: symptomatic treatments for agitation and psychosis. CNS Spectr. 2018 Oct; 23(5):291-297. PMID: 30382934.
      View in: PubMed
    2. Stahl SM. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other? CNS Spectr. 2018 Aug; 23(4):239-247. PMID: 30160230.
      View in: PubMed
    3. Stahl SM. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate. CNS Spectr. 2018 Jun; 23(3):187-191. PMID: 29954475.
      View in: PubMed
    4. Stahl SM. Antagonist treatment is just as effective as replacement therapy for opioid addiction but neither is used often enough. CNS Spectr. 2018 Apr; 23(2):113-116. PMID: 29676241.
      View in: PubMed
    5. Marazziti D, Stahl SM. Serotonin and Love: Supporting Evidence From a Patient Suffering From Obsessive-Compulsive Disorder. J Clin Psychopharmacol. 2018 Feb; 38(1):99-101. PMID: 29189409.
      View in: PubMed
    6. Stahl SM. Mixed-up about how to diagnose and treat mixed features in major depressive episodes - CORRIGENDUM. CNS Spectr. 2018 Apr; 23(2):185. PMID: 29353558.
      View in: PubMed
    7. Cummings MA, Proctor GJ, Stahl SM. Deuterium Tetrabenazine for Tardive Dyskinesia. Clin Schizophr Relat Psychoses. 2018 Jan; 11(4):214-220. PMID: 29341821.
      View in: PubMed
    8. Stahl SM. Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less "go" and more "stop" from the motor striatum for robust therapeutic effects. CNS Spectr. 2018 Feb; 23(1):1-6. PMID: 29249207.
      View in: PubMed
    9. Stahl SM. Neuronal traffic signals in tardive dyskinesia: not enough "stop" in the motor striatum. CNS Spectr. 2017 Dec; 22(6):427-434. PMID: 29205123.
      View in: PubMed
    10. Lemoine P, Stahl SM. Conditions of life and death of psychiatric patients in France during World War II: euthanasia or collateral casualties? CNS Spectr. 2018 Apr; 23(2):170-175. PMID: 29081316.
      View in: PubMed
    11. Stahl SM. Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes. CNS Spectr. 2017 Oct; 22(5):375-384. PMID: 28965530.
      View in: PubMed
    12. Stahl SM, Morrissette DA. Does a "whiff" of mania in a major depressive episode shift treatment from a classical antidepressant to an atypical/second-generation antipsychotic? Bipolar Disord. 2017 11; 19(7):595-596. PMID: 28895270.
      View in: PubMed
    13. Marazziti D, Stahl SM. Evil, terrorism, and psychiatry. CNS Spectr. 2018 Apr; 23(2):117-118. PMID: 28870267.
      View in: PubMed
    14. Stahl SM. Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors. CNS Spectr. 2017 Aug; 22(4):305-311. PMID: 28758887.
      View in: PubMed
    15. Moore BA, Morrissette DA, Meyer JM, Stahl SM. Drug information update. Unconventional treatment strategies for schizophrenia: polypharmacy and heroic dosing. BJPsych Bull. 2017 Jun; 41(3):164-168. PMID: 28584654.
      View in: PubMed
    16. Shapiro D, Stevens D, Stahl SM. Flibanserin - the female Viagra? Int J Psychiatry Clin Pract. 2017 Nov; 21(4):259-265. PMID: 28434386.
      View in: PubMed
    17. Stahl SM. Does treating hearing loss prevent or slow the progress of dementia? Hearing is not all in the ears, but who's listening? CNS Spectr. 2017 Jun; 22(3):247-250. PMID: 28376938.
      View in: PubMed
    18. Keppel Hesselink JM, Kopsky DJ, Stahl SM. Bottlenecks in the development of topical analgesics: molecule, formulation, dose-finding, and phase III design. J Pain Res. 2017; 10:635-641. PMID: 28360532.
      View in: PubMed
    19. Stahl SM. Mixed-up about how to diagnose and treat mixed features in major depressive episodes. CNS Spectr. 2017 Apr; 22(2):111-115. PMID: 28271818.
      View in: PubMed
    20. Stahl SM, Morrissette DA, Faedda G, Fava M, Goldberg JF, Keck PE, Lee Y, Malhi G, Marangoni C, McElroy SL, Ostacher M, Rosenblat JD, Solé E, Suppes T, Takeshima M, Thase ME, Vieta E, Young A, Zimmerman M, McIntyre RS. Guidelines for the recognition and management of mixed depression. CNS Spectr. 2017 Apr; 22(2):203-219. PMID: 28421980.
      View in: PubMed
    21. Stahl SM. Psychiatric Pharmacogenomics: How to Integrate into Clinical Practice. CNS Spectr. 2017 Feb; 22(1):1-4. PMID: 28168945.
      View in: PubMed
    22. Stahl SM. Kick-Off Editorial for 2017: CNS Spectrums Is on the Move. CNS Spectr. 2017 Feb; 22(1):5-6. PMID: 28168944.
      View in: PubMed
    23. Nutt D, Stahl S, Blier P, Drago F, Zohar J, Wilson S. Inverse agonists - What do they mean for psychiatry? Eur Neuropsychopharmacol. 2017 01; 27(1):87-90. PMID: 27955830.
      View in: PubMed
    24. Meyer JM, Cummings MA, Proctor G, Stahl SM. Psychopharmacology of Persistent Violence and Aggression. Psychiatr Clin North Am. 2016 Dec; 39(4):541-556. PMID: 27836150.
      View in: PubMed
    25. Stahl SM. Dextromethorphan-quinidine-responsive pseudobulbar affect (PBA): psychopharmacological model for wide-ranging disorders of emotional expression? CNS Spectr. 2016 Dec; 21(6):419-423. PMID: 27855728.
      View in: PubMed
    26. Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, Pfaus J, Simon JA, Kingsberg SA, Meston C, Stahl SM, Wallen K, Worsley R. Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review. Mayo Clin Proc. 2017 Jan; 92(1):114-128. PMID: 27916394.
      View in: PubMed
    27. Meyer JM, Proctor G, Cummings MA, Dardashti LJ, Stahl SM. Ciprofloxacin and Clozapine: A Potentially Fatal but Underappreciated Interaction. Case Rep Psychiatry. 2016; 2016:5606098. PMID: 27872784.
      View in: PubMed
    28. Stahl SM. Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome. CNS Spectr. 2016 Oct; 21(5):355-359. PMID: 27686027.
      View in: PubMed
    29. Stahl SM. Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors. CNS Spectr. 2016 Aug; 21(4):271-5. PMID: 27503570.
      View in: PubMed
    30. Stahl SM. Mechanism of action of suvorexant. CNS Spectr. 2016 Jun; 21(3):215-8. PMID: 27322687.
      View in: PubMed
    31. Stahl SM. Using neuroscience for naming psychotropic drugs. CNS Spectr. 2016 Jun; 21(3):219-20. PMID: 27322688.
      View in: PubMed
    32. Stahl SM. Mechanism of action of cariprazine. CNS Spectr. 2016 Apr; 21(2):123-7. PMID: 26956157.
      View in: PubMed
    33. Stahl SM. Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr. 2016 Feb; 21(1):1-6. PMID: 26899451.
      View in: PubMed
    34. Zohar J, Stahl S, Moller HJ, Blier P, Kupfer D, Yamawaki S, Uchida H, Spedding M, Goodwin GM, Nutt D. A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur Neuropsychopharmacol. 2015 Dec; 25(12):2318-25. PMID: 26527055.
      View in: PubMed
    35. Culpepper L, Muskin PR, Stahl SM. Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability. Am J Med. 2015 Sep; 128(9 Suppl):S1-S15. PMID: 26337210.
      View in: PubMed
    36. Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine. CNS Spectr. 2015 Oct; 20(5):455-9. PMID: 26122791.
      View in: PubMed
    37. Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin's downstream effects on glutamate and GABA (gamma amino butyric acid) release. CNS Spectr. 2015 Aug; 20(4):331-6. PMID: 26062900.
      View in: PubMed
    38. Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters. CNS Spectr. 2015 Dec; 20(6):515-9. PMID: 26062986.
      View in: PubMed
    39. Warburton KD, Stahl SM. Treat the treatable: a comprehensive and optimistic approach to treating psychiatric violence. CNS Spectr. 2015 Jun; 20(3):170-1. PMID: 25997604.
      View in: PubMed
    40. Stahl SM. Is impulsive violence an addiction? The Habit Hypothesis. CNS Spectr. 2015 Jun; 20(3):165-9. PMID: 25912294.
      View in: PubMed
    41. Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). CNS Spectr. 2015 Apr; 20(2):93-7. PMID: 25831967.
      View in: PubMed
    42. Schaufenbil RJ, Kornbluh R, Stahl SM, Warburton KD. Forensic focused treatment planning: a new standard for forensic mental health systems. CNS Spectr. 2015 Jun; 20(3):250-3. PMID: 25801440.
      View in: PubMed
    43. Morrissette DA, Stahl SM. Modulating the serotonin system in the treatment of major depressive disorder-ERRATUM. CNS Spectr. 2015 Aug; 20(4):452-3. PMID: 25731078.
      View in: PubMed
    44. Stahl SM. Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. CNS Spectr. 2015 Feb; 20(1):1-6. PMID: 25659981.
      View in: PubMed
    45. Morrissette DA, Stahl SM. Modulating the serotonin system in the treatment of major depressive disorder. CNS Spectr. 2014 Dec; 19 Suppl 1:57-67; quiz 54-7, 68. PMID: 25544378.
      View in: PubMed
    46. Stahl SM. Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients. CNS Spectr. 2014 Dec; 19(6):475-8. PMID: 25422900.
      View in: PubMed
    47. Stahl SM. Deconstructing violence as a medical syndrome: mapping psychotic, impulsive, and predatory subtypes to malfunctioning brain circuits. CNS Spectr. 2014 Oct; 19(5):357-65. PMID: 25296964.
      View in: PubMed
    48. Stahl SM, Morrissette DA, Cummings M, Azizian A, Bader S, Broderick C, Dardashti L, Delgado D, Meyer J, O'Day J, Proctor G, Rose B, Schur M, Schwartz E, Velasquez S, Warburton K. California State Hospital Violence Assessment and Treatment (Cal-VAT) guideline. CNS Spectr. 2014 Oct; 19(5):449-65. PMID: 27358935.
      View in: PubMed
    49. Stahl SM, Morrissette DA, Cummings M, Azizian A, Bader S, Broderick C, Dardashti L, Delgado D, Meyer J, O'Day J, Proctor G, Rose B, Schur M, Schwartz E, Velasquez S, Warburton K. California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines. CNS Spectr. 2014 Oct; 19(5):449-465. PMID: 28480838.
      View in: PubMed
    50. Morrissette DA, Stahl SM. Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectr. 2014 Oct; 19(5):439-48. PMID: 25119976.
      View in: PubMed
    51. Stahl SM. Clozapine: is now the time for more clinicians to adopt this orphan? CNS Spectr. 2014 Aug; 19(4):279-81. PMID: 25267329.
      View in: PubMed
    52. Papakostas GI, Shelton RC, Zajecka JM, Bottiglieri T, Roffman J, Cassiello C, Stahl SM, Fava M. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry. 2014 Aug; 75(8):855-63. PMID: 24813065.
      View in: PubMed
    53. Stahl SM. Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties. CNS Spectr. 2014 Jun; 19(3):207-12. PMID: 24901504.
      View in: PubMed
    54. Stahl SM. Mechanism of action of the SPARI vilazodone: serotonin 1A partial agonist and reuptake inhibitor. CNS Spectr. 2014 Apr; 19(2):105-9. PMID: 24673885.
      View in: PubMed
    55. Stahl SM. Long-acting injectable antipsychotics: shall the last be first? CNS Spectr. 2014 Feb; 19(1):3-5. PMID: 24512639.
      View in: PubMed
    56. Stahl SM. Role of a1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms. CNS Spectr. 2013 Dec; 18(6):285-8. PMID: 24300463.
      View in: PubMed
    57. Grady MM, Stahl SM. Novel agents in development for the treatment of depression. CNS Spectr. 2013 Dec; 18 Suppl 1:37-40; quiz 41. PMID: 24252548.
      View in: PubMed
    58. Opler LA, Medalia A, Opler MG, Stahl SM. Pharmacotherapy of cognitive deficits in schizophrenia. CNS Spectr. 2014 Apr; 19(2):142-56. PMID: 24229725.
      View in: PubMed
    59. Stahl SM. Mechanism of action of dextromethorphan/quinidine:comparison with ketamine. CNS Spectr. 2013 Oct; 18(5):225-7. PMID: 24050154.
      View in: PubMed
    60. Zohar J, Nutt DJ, Kupfer DJ, Moller HJ, Yamawaki S, Spedding M, Stahl SM. A proposal for an updated neuropsychopharmacological nomenclature. Eur Neuropsychopharmacol. 2014 Jul; 24(7):1005-14. PMID: 24630385.
      View in: PubMed
    61. Stahl SM. Controversies in treating bipolar depression. CNS Spectr. 2013 Aug; 18(4):175-6. PMID: 23866090.
      View in: PubMed
    62. Translating from neuroscience to psychiatry (and back translating from psychiatry to neuroscience). Acta Psychiatr Scand. 2013 Aug; 128(2):103-4. PMID: 23829230.
      View in: PubMed
    63. Stahl SM. Mechanism of action of ketamine. CNS Spectr. 2013 Aug; 18(4):171-4. PMID: 23866089.
      View in: PubMed
    64. Stahl SM, Morrissette DA, Citrome L, Saklad SR, Cummings MA, Meyer JM, O'Day JA, Dardashti LJ, Warburton KD. “Meta-guidelines” for the management of patients with schizophrenia. CNS Spectr. 2013 Jun; 18(3):150-162. PMID: 23591126.
      View in: PubMed
    65. Stahl SM. Classifying psychotropic drugs by mode of action and not by target disorder. CNS Spectr. 2013 Jun; 18(3):113-7. PMID: 23706705.
      View in: PubMed
    66. Stahl SM, Porreca F, Taylor CP, Cheung R, Thorpe AJ, Clair A. The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities? Trends Pharmacol Sci. 2013 Jun; 34(6):332-9. PMID: 23642658.
      View in: PubMed
    67. Stahl SM, Lee-Zimmerman C, Cartwright S, Morrissette DA. Serotonergic drugs for depression and beyond. Curr Drug Targets. 2013 May 01; 14(5):578-85. PMID: 23531115.
      View in: PubMed
    68. Stahl SM. The last Diagnostic and Statistical Manual (DSM): replacing our symptom-based diagnoses with a brain circuit-based classification of mental illnesses. CNS Spectr. 2013 Apr; 18(2):65-8. PMID: 23691552.
      View in: PubMed
    69. Stahl SM, Cucchiaro J, Simonelli D, Hsu J, Pikalov A, Loebel A. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013 May; 74(5):507-15. PMID: 23541189.
      View in: PubMed
    70. Stahl SM. Emerging guidelines for the use of antipsychotic polypharmacy. Rev Psiquiatr Salud Ment. 2013 Jul-Sep; 6(3):97-100. PMID: 23485567.
      View in: PubMed
    71. Stahl SM. Off-label prescribing: best practice or malpractice? CNS Spectr. 2013 Feb; 18(1):1-4. PMID: 23593650.
      View in: PubMed
    72. Stahl SM. The tyranny of the majority and the interchangeability of drugs. Acta Psychiatr Scand. 2013 Jan; 127(1):4-5. PMID: 23240592.
      View in: PubMed
    73. Schwartz TL, Sachdeva S, Stahl SM. Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol. 2012; 3:195. PMID: 23189055; PMCID: PMC3505861.
    74. Morrissette DA, Stahl SM. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment. CNS Spectr. 2012 Nov; 17 Suppl 1:10-21. PMID: 23462201.
      View in: PubMed
    75. Griebel G, Beeské S, Stahl SM. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry. 2012 Nov; 73(11):1403-11. PMID: 23146246.
      View in: PubMed
    76. Lum CT, Stahl SM. Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression. CNS Spectr. 2012 Sep; 17(3):107-20. PMID: 23888494.
      View in: PubMed
    77. Tarazi FI, Stahl SM. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012 Sep; 13(13):1911-22. PMID: 22849428.
      View in: PubMed
    78. Grady MM, Stahl SM. A horse of a different color: how formulation influences medication effects. CNS Spectr. 2012 Jun; 17(2):63-9. PMID: 22789063.
      View in: PubMed
    79. Stahl SM. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr Scand. 2012 May; 125(5):349-51. PMID: 22506490.
      View in: PubMed
    80. Grady MM, Stahl SM. Practical guide for prescribing MAOIs: debunking myths and removing barriers. CNS Spectr. 2012 Mar; 17(1):2-10. PMID: 22790112.
      View in: PubMed
    81. Brandt MR, Beyer CE, Stahl SM. TRPV1 Antagonists and Chronic Pain: Beyond Thermal Perception. Pharmaceuticals (Basel). 2012 Feb 02; 5(2):114-32. PMID: 24288084; PMCID: PMC3763634.
    82. Schwartz TL, Sachdeva S, Stahl SM. Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia. Curr Pharm Des. 2012; 18(12):1580-92. PMID: 22280435.
      View in: PubMed
    83. Citrome L, Meng X, Hochfeld M, Stahl SM. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. Hum Psychopharmacol. 2012 Jan; 27(1):24-32. PMID: 22161738.
      View in: PubMed
    84. Schwartz TL, Siddiqui UA, Stahl SM. Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor. Ther Adv Psychopharmacol. 2011 Jun; 1(3):81-7. PMID: 23983930; PMCID: PMC3736894.
    85. Schwartz TL, Stahl SM. Treatment strategies for dosing the second generation antipsychotics. CNS Neurosci Ther. 2011 Apr; 17(2):110-7. PMID: 21401911.
      View in: PubMed
    86. Mattei C, Rapagnani MP, Stahl SM. Ziprasidone hydrocloride: what role in the management of schizophrenia? J Cent Nerv Syst Dis. 2011; 3:1-16. PMID: 23861634; PMCID: PMC3663608.
    87. Stahl SM, Lonnen AJ. The Mechanism of Drug-induced Akathsia. CNS Spectr. 2011 Jan 15. PMID: 21406165.
      View in: PubMed
    88. Loonen AJ, Stahl SM. Functional psychopharmacology is the way to go in pharmacotherapy for psychiatric disorders. Acta Psychiatr Scand. 2010 Dec; 122(6):435-7. PMID: 21054280.
      View in: PubMed
    89. Stahl SM. The serotonin-7 receptor as a novel therapeutic target. J Clin Psychiatry. 2010 Nov; 71(11):1414-5. PMID: 21114946.
      View in: PubMed
    90. Stahl SM. How to dose a psychotropic drug: beyond therapeutic drug monitoring to genotyping the patient. Acta Psychiatr Scand. 2010 Dec; 122(6):440-1. PMID: 20880158.
      View in: PubMed
    91. Stahl SM, Sommer B, Allers KA. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med. 2011 Jan; 8(1):15-27. PMID: 20840530.
      View in: PubMed
    92. Stahl SM. Illustrating the circuits of sexual desire. J Clin Psychiatry. 2010 Sep; 71(9):1113-4. PMID: 20923619.
      View in: PubMed
    93. Stahl SM, Malla A, Newcomer JW, Potkin SG, Weiden PJ, Harvey PD, Loebel A, Watsky E, Siu CO, Romano S. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. J Clin Psychopharmacol. 2010 Aug; 30(4):425-30. PMID: 20571437.
      View in: PubMed
    94. Stahl SM, Davis RL, Kim DH, Lowe NG, Carlson RE, Fountain K, Grady MM. Play it Again: The Master Psychopharmacology Program as an Example of Interval Learning in Bite-Sized Portions. CNS Spectr. 2010 Aug; 15(8):491-504. PMID: 20703196.
      View in: PubMed
    95. Stahl SM. Targeting circuits of sexual desire as a treatment strategy for hypoactive sexual desire disorder. J Clin Psychiatry. 2010 Jul; 71(7):821-2. PMID: 20667289.
      View in: PubMed
    96. Stahl SM. Fooling mother nature: epigenetics and novel treatments for psychiatric disorders. CNS Spectr. 2010 Jun; 15(6):358-65. PMID: 20625368.
      View in: PubMed
    97. Stahl SM. Psychiatric stress testing: novel strategy for translational psychopharmacology. Neuropsychopharmacology. 2010 Jun; 35(7):1413-4. PMID: 20463680; PMCID: PMC3055455.
    98. Stahl SM. Circuits of sexual desire in hypoactive sexual desire disorder. J Clin Psychiatry. 2010 May; 71(5):518-9. PMID: 20492849.
      View in: PubMed
    99. Stahl SM. Methylated spirits: epigenetic hypotheses of psychiatric disorders. CNS Spectr. 2010 Apr; 15(4):220-30. PMID: 20414171.
      View in: PubMed
    100. Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010 Apr; 30(2):135-44. PMID: 20520286.
      View in: PubMed
    101. Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry. 2010 May; 71(5):616-26. PMID: 20361916.
      View in: PubMed
    102. Stahl SM. Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms. J Clin Psychiatry. 2010 Mar; 71(3):223-4. PMID: 20331927.
      View in: PubMed
    103. Stahl SM. Enhancing outcomes from major depression: using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. CNS Spectr. 2010 Feb; 15(2):79-94. PMID: 20414154.
      View in: PubMed
    104. Kim DH, Stahl SM. Antipsychotic drug development. Curr Top Behav Neurosci. 2010; 4:123-39. PMID: 21312399.
      View in: PubMed
    105. Stahl SM. Mechanism of action of stimulants in attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2010 Jan; 71(1):12-3. PMID: 20129003.
      View in: PubMed
    106. Stahl SM. Crisis in army psychopharmacology and mental health care at Fort Hood. CNS Spectr. 2009 Dec; 14(12):677-84. PMID: 20394175.
      View in: PubMed
    107. Stahl SM. Combining antidepressant therapies from the initiation of treatment: a paradigm shift for major depression. J Clin Psychiatry. 2009 Nov; 70(11):1493-4. PMID: 20031093.
      View in: PubMed
    108. Mignon L, Stahl SM. Clinical management of major depressive disorder. CNS Spectr. 2009 Nov; 14(11 Suppl 10):3-6; quiz 7-8. PMID: 20173690.
      View in: PubMed
    109. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009 Oct; 14(10):536-46. PMID: 20095366.
      View in: PubMed
    110. Stahl SM. Epigenetics and methylomics in psychiatry. J Clin Psychiatry. 2009 Sep; 70(9):1204-5. PMID: 19818242.
      View in: PubMed
    111. Stahl SM, Davis RL. Applying the principles of adult learning to the teaching of psychopharmacology: audience response systems. CNS Spectr. 2009 Aug; 14(8):412-4. PMID: 19890234.
      View in: PubMed
    112. Stahl SM. The prefrontal cortex is out of tune in attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2009 Jul; 70(7):950-1. PMID: 19653972.
      View in: PubMed
    113. Stahl SM, Davis RL. Applying the principles of adult learning to the teaching of psychopharmacology: storyboarding a presentation and the rule of small multiples. CNS Spectr. 2009 Jun; 14(6):288-94. PMID: 19668120.
      View in: PubMed
    114. Munk-Jørgensen P, Nielsen J, Nielsen RE, Stahl SM. Last episode psychosis. Acta Psychiatr Scand. 2009 Jun; 119(6):417-8. PMID: 19469724.
      View in: PubMed
    115. Stahl SM. Fibromyalgia--pathways and neurotransmitters. Hum Psychopharmacol. 2009 Jun; 24 Suppl 1:S11-7. PMID: 19479906.
      View in: PubMed
    116. Stahl SM, Briley M. Why psychiatrists should not ignore pain in their patients--focus on fibromyalgia? Hum Psychopharmacol. 2009 Jun; 24 Suppl 1:S1-2. PMID: 19479908.
      View in: PubMed
    117. Stahl SM. Norepinephrine and dopamine regulate signals and noise in the prefrontal cortex. J Clin Psychiatry. 2009 May; 70(5):617-8. PMID: 19552863.
      View in: PubMed
    118. Stahl SM, Davis RL. Applying the principles of adult learning to the teaching of psychopharmacology: overview and finding the focus. CNS Spectr. 2009 Apr; 14(4):179-82. PMID: 19407729.
      View in: PubMed
    119. Stahl SM. Vasomotor symptoms and depression in women, part 2. Treatments that cause remission and prevent relapses of major depressive episodes overlap with treatments for vasomotor symptoms. J Clin Psychiatry. 2009 Mar; 70(3):310-1. PMID: 19317957.
      View in: PubMed
    120. Stahl SM. Multifunctional drugs: a novel concept for psychopharmacology. CNS Spectr. 2009 Feb; 14(2):71-3. PMID: 19238121.
      View in: PubMed
    121. Stahl SM. Vasomotor symptoms and depression in women, part I. Role of vasomotor symptoms in signaling the onset or relapse of a major depressive episode. J Clin Psychiatry. 2009 Jan; 70(1):11-2. PMID: 19222980.
      View in: PubMed
    122. Kim DH, Maneen MJ, Stahl SM. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics. 2009 Jan; 6(1):78-85. PMID: 19110200.
      View in: PubMed
    123. Stahl SM. Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec; 13(12):1027-38. PMID: 19179941.
      View in: PubMed
    124. Stahl SM. The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition? J Clin Psychiatry. 2008 Nov; 69(11):1673-4. PMID: 19200426.
      View in: PubMed
    125. Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008 Oct; 13(10):855-70. PMID: 18955941.
      View in: PubMed
    126. Stahl SM. L-methylfolate: a vitamin for your monoamines. J Clin Psychiatry. 2008 Sep; 69(9):1352-3. PMID: 19193337.
      View in: PubMed
    127. Wise DD, Felker A, Stahl SM. Tailoring treatment of depression for women across the reproductive lifecycle: the importance of pregnancy, vasomotor symptoms, and other estrogen-related events in psychopharmacology. CNS Spectr. 2008 Aug; 13(8):647-62. PMID: 18704021.
      View in: PubMed
    128. Papakostas GI, Stahl SM, Krishen A, Seifert CA, Tucker VL, Goodale EP, Fava M. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry. 2008 Aug; 69(8):1287-92. PMID: 18605812.
      View in: PubMed
    129. Stahl SM, Wise DD. The potential role of a corticotropin-releasing factor receptor-1 antagonist in psychiatric disorders. CNS Spectr. 2008 Jun; 13(6):467-83. PMID: 18567971.
      View in: PubMed
    130. Cutler A, Ball S, Stahl SM. Dosing atypical antipsychotics. CNS Spectr. 2008 May; 13(5 Suppl 9):1-16. PMID: 18496483.
      View in: PubMed
    131. Stahl SM. Do dopamine partial agonists have partial efficacy as antipsychotics? CNS Spectr. 2008 Apr; 13(4):279-82. PMID: 18408646.
      View in: PubMed
    132. Stahl SM. Personalized medicine, pharmacogenomics, and the practice of psychiatry: on the threshold of predictive therapeutics in psychopharmacology? CNS Spectr. 2008 Feb; 13(2):115-8. PMID: 18227742.
      View in: PubMed
    133. Zisook S, Glick ID, Jefferson JW, Wagner KD, Salzman C, Peselow ED, Stahl S. Teaching psychopharmacology: what works and what doesn't. J Clin Psychopharmacol. 2008 Feb; 28(1):96-100. PMID: 18204350.
      View in: PubMed
    134. Rupnow MF, Greenspan A, Gharabawi GM, Kosik-Gonzalez C, Zhu Y, Stahl SM. Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. Curr Med Res Opin. 2007 Nov; 23(11):2815-22. PMID: 17910802.
      View in: PubMed
    135. Stahl SM. Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent. CNS Spectr. 2007 Oct; 12(10):739-44. PMID: 17934378.
      View in: PubMed
    136. Stahl SM, Ahmed S, Haudiquet V. Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER. CNS Spectr. 2007 Sep; 12(9):703-11. PMID: 17805217.
      View in: PubMed
    137. Stahl SM. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int J Neuropsychopharmacol. 2007 Oct; 10(5):575-8. PMID: 17681087.
      View in: PubMed
    138. Stahl SM. The genetics of schizophrenia converge upon the NMDA glutamate receptor. CNS Spectr. 2007 Aug; 12(8):583-8. PMID: 17667886.
      View in: PubMed
    139. Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci. 2007 Jul; 28(7):316-25. PMID: 17573127.
      View in: PubMed
    140. Stahl SM. Novel therapeutics for schizophrenia: targeting glycine modulation of NMDA glutamate receptors. CNS Spectr. 2007 Jun; 12(6):423-7. PMID: 17545952.
      View in: PubMed
    141. Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Françon D, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, le Fur G, Griebel G. Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology. 2008 Feb; 33(3):574-87. PMID: 17460614.
      View in: PubMed
    142. Stahl SM. Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. CNS Spectr. 2007 Apr; 12(4):265-8. PMID: 17426663.
      View in: PubMed
    143. Stahl SM. Overview of trends in modern psychopharmacology. CNS Spectr. 2007 Feb; 12(2):103-5. PMID: 17277709.
      View in: PubMed
    144. Stahl SM. Positive findings for negative symptoms of schizophrenia: no longer untreatable? Acta Psychiatr Scand. 2006 Nov; 114(5):301-2. PMID: 17022789.
      View in: PubMed
    145. Rausch JL, Johnson ME, Kasik KE, Stahl SM. Temperature regulation in depression: functional 5HT1A receptor adaptation differentiates antidepressant response. Neuropsychopharmacology. 2006 Oct; 31(10):2274-80. PMID: 16641936.
      View in: PubMed
    146. Stahl SM, Grady MM. High-cost use of second-generation antipsychotics under California's Medicaid program. Psychiatr Serv. 2006 Jan; 57(1):127-9. PMID: 16399974.
      View in: PubMed
    147. Stahl SM. Finding what you are not looking for: strategies for developing novel treatments in psychiatry. NeuroRx. 2006 Jan; 3(1):3-9. PMID: 16490409; PMCID: PMC3593354.
    148. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005 Sep; 10(9):732-47. PMID: 16142213.
      View in: PubMed
    149. Shayegan DK, Stahl SM. Emotion processing, the amygdala, and outcome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun; 29(5):840-5. PMID: 15925435.
      View in: PubMed
    150. Stahl SM. Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. CNS Spectr. 2005 Apr; 10(4):319-23. PMID: 15788959.
      View in: PubMed
    151. Citrome L, Goldberg JF, Stahl SM. Toward convergence in the medication treatment of bipolar disorder and schizophrenia. Harv Rev Psychiatry. 2005 Jan-Feb; 13(1):28-42. PMID: 15804932.
      View in: PubMed
    152. Stahl SM. Is psychopharmacologic "inoculation" effective in preventing posttraumatic stress disorder? J Clin Psychiatry. 2005 Jan; 66(1):5-6. PMID: 15669882.
      View in: PubMed
    153. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnston JA. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005; 7(3):106-13. PMID: 16027765; PMCID: PMC1163271.
    154. Stahl SM. Preemptive analgesia: is pain less costly when you pre-pay for it? J Clin Psychiatry. 2004 Dec; 65(12):1591-2. PMID: 15641861.
      View in: PubMed
    155. Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry. 2004 Dec; 65(12):1715-9. PMID: 15641878.
      View in: PubMed
    156. Stahl SM. Prophylactic antipsychotics: do they keep you from catching schizophrenia? J Clin Psychiatry. 2004 Nov; 65(11):1445-6. PMID: 15554754.
      View in: PubMed
    157. Demyttenaere K, De Fruyt J, Stahl SM. The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacol. 2005 Mar; 8(1):93-105. PMID: 15482632.
      View in: PubMed
    158. Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr. 2004 Oct; 9(10 Suppl 11):6-14. PMID: 15475871.
      View in: PubMed
    159. Stahl SM. Drug combinations for bipolar spectrum disorders: evidence-based prescribing or prescribing-based evidence? J Clin Psychiatry. 2004 Oct; 65(10):1298-9. PMID: 15491230.
      View in: PubMed
    160. Stahl S, Freudenreich O, Goff D. A successful antipsychotic combination trial. Quo Vadis? Acta Psychiatr Scand. 2004 Oct; 110(4):241-2. PMID: 15352924.
      View in: PubMed
    161. Stahl S, Briley M. Understanding pain in depression. Hum Psychopharmacol. 2004 Oct; 19 Suppl 1:S9-S13. PMID: 15378669.
      View in: PubMed
    162. Stahl SM. Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator. J Clin Psychiatry. 2004 Sep; 65(9):1162-3. PMID: 15367040.
      View in: PubMed
    163. Gelenberg AJ, Shelton RC, Crits-Christoph P, Keller MB, Dunner DL, Hirschfeld RM, Thase ME, Russell JM, Lydiard RB, Gallop RJ, Todd L, Hellerstein DJ, Goodnick PJ, Keitner GI, Stahl SM, Halbreich U, Hopkins HS. The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. J Clin Psychiatry. 2004 Aug; 65(8):1114-9. PMID: 15323598.
      View in: PubMed
    164. Stahl SM. Mechanism of action of alpha2delta ligands: voltage sensitive calcium channel (VSCC) modulators. J Clin Psychiatry. 2004 Aug; 65(8):1033-4. PMID: 15323585.
      View in: PubMed
    165. Stahl SM. Mechanism of action of voltage sensitive sodium channel modulators. J Clin Psychiatry. 2004 Jul; 65(7):894-5. PMID: 15291674.
      View in: PubMed
    166. Stahl SM. Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels. J Clin Psychiatry. 2004 Jun; 65(6):738-9. PMID: 15291647.
      View in: PubMed
    167. Stahl SM. Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels. J Clin Psychiatry. 2004 May; 65(5):596-7. PMID: 15163243.
      View in: PubMed
    168. Stahl SM, Markowitz JS, Papadopoulos G, Sadik K. Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease. Curr Med Res Opin. 2004 Apr; 20(4):517-24. PMID: 15119989.
      View in: PubMed
    169. Stahl SM. Anticonvulsants as anxiolytics, part 2: Pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels. J Clin Psychiatry. 2004 Apr; 65(4):460-1. PMID: 15119905.
      View in: PubMed
    170. Stahl SM. Anticonvulsants as anxiolytics, part 1: tiagabine and other anticonvulsants with actions on GABA. J Clin Psychiatry. 2004 Mar; 65(3):291-2. PMID: 15096065.
      View in: PubMed
    171. Stahl SM. Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence? Int J Neuropsychopharmacol. 2004 Jun; 7(2):113-6. PMID: 14984629.
      View in: PubMed
    172. Stahl SM. Psychopharmacology of anticonvulsants: do all anticonvulsants have the same mechanism of action? J Clin Psychiatry. 2004 Feb; 65(2):149-50. PMID: 15003065.
      View in: PubMed
    173. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry. 2004; 6(4):159-166. PMID: 15361919.
      View in: PubMed
    174. Stahl SM. Selectivity of SSRIs: individualising patient care through rational treatment choices. Int J Psychiatry Clin Pract. 2004; 8 Suppl 1:3-10. PMID: 24930682.
      View in: PubMed
    175. Stahl SM. Symptoms and circuits, part 3: schizophrenia. J Clin Psychiatry. 2004 Jan; 65(1):8-9. PMID: 14744162.
      View in: PubMed
    176. Stahl SM. Brainstorms: symptoms and circuits, part 2: anxiety disorders. J Clin Psychiatry. 2003 Dec; 64(12):1408-9. PMID: 14728099.
      View in: PubMed
    177. Stahl SM. Symptoms and circuits, part 1: major depressive disorder. J Clin Psychiatry. 2003 Nov; 64(11):1282-3. PMID: 14658940.
      View in: PubMed
    178. Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2003 Nov; 64(11):1322-7. PMID: 14658946.
      View in: PubMed
    179. Stahl SM. Deconstructing psychiatric disorders, part 2: An emerging, neurobiologically based therapeutic strategy for the modern psychopharmacologist. J Clin Psychiatry. 2003 Oct; 64(10):1145-6. PMID: 14658960.
      View in: PubMed
    180. Stahl SM. Deconstructing psychiatric disorders, Part 1. Genotypes, symptom phenotypes, and endophenotypes. J Clin Psychiatry. 2003 Sep; 64(9):982-3. PMID: 14628971.
      View in: PubMed
    181. Stahl SM. Here today and not gone tomorrow: the curse of chronic pain and other central sensitization syndromes. J Clin Psychiatry. 2003 Aug; 64(8):863-4. PMID: 12926998.
      View in: PubMed
    182. Stahl SM. Antidepressants and somatic symptoms: therapeutic actions are expanding beyond affective spectrum disorders to functional somatic syndromes. J Clin Psychiatry. 2003 Jul; 64(7):745-6. PMID: 12934972.
      View in: PubMed
    183. Stahl SM. The ups and downs of novel antiemetic drugs, part 2: an illustration. J Clin Psychiatry. 2003 Jun; 64(6):626-7. PMID: 12823074.
      View in: PubMed
    184. Stahl SM. The ups and downs of novel antiemetic drugs, part 1: substance P, 5-HT, and the neuropharmacology of vomiting. J Clin Psychiatry. 2003 May; 64(5):498-9. PMID: 12755650.
      View in: PubMed
    185. Stahl SM. At long last, long-lasting psychiatric medications: an overview of controlled-release technologies. J Clin Psychiatry. 2003 Apr; 64(4):355-6. PMID: 12716234.
      View in: PubMed
    186. Stahl SM, Markowitz JS, Gutterman EM, Papadopoulos G. Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community. J Clin Psychiatry. 2003 Apr; 64(4):466-72. PMID: 12716251.
      View in: PubMed
    187. Stahl SM. Neurotransmission of cognition, part 3. Mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortex. J Clin Psychiatry. 2003 Mar; 64(3):230-1. PMID: 12716261.
      View in: PubMed
    188. Stahl SM. Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. J Clin Psychiatry. 2003 Feb; 64(2):110-1. PMID: 12633117.
      View in: PubMed
    189. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003; 64 Suppl 19:6-12. PMID: 14728084.
      View in: PubMed
    190. Stahl SM. Neurotransmission of cognition, part 1, Dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamine. J Clin Psychiatry. 2003 Jan; 64(1):4-5. PMID: 12590617.
      View in: PubMed
    191. Hollander E, Kaplan A, Stahl SM. A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatry. 2003 Jan; 4(1):30-4. PMID: 12582975.
      View in: PubMed
    192. Stahl SM, Grady MM. Differences in mechanism of action between current and future antidepressants. J Clin Psychiatry. 2003; 64 Suppl 13:13-7. PMID: 14552651.
      View in: PubMed
    193. Stahl SM. Introduction: optimizing wakefulness in patients with fatigue and executive dysfunction. J Clin Psychiatry. 2003; 64 Suppl 14:3-4. PMID: 14658928.
      View in: PubMed
    194. Stahl SM, Zhang L, Damatarca C, Grady M. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry. 2003; 64 Suppl 14:6-17. PMID: 14658930.
      View in: PubMed
    195. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry. 2002 Dec 15; 52(12):1166-74. PMID: 12488062.
      View in: PubMed
    196. Stahl SM. The metabolic syndrome: psychopharmacologists should weigh the evidence for weighing the patient. J Clin Psychiatry. 2002 Dec; 63(12):1094-5. PMID: 12523866.
      View in: PubMed
    197. Lutz W, Stahl SM, Howard KI, Grissom GR, Joske R. Some relationships among assessments of depression. J Clin Psychol. 2002 Dec; 58(12):1545-53. PMID: 12455021.
      View in: PubMed
    198. Stahl SM. Can psychopharmacologic treatments that relieve symptoms also prevent disease progression? J Clin Psychiatry. 2002 Nov; 63(11):961-2. PMID: 12444807.
      View in: PubMed
    199. Stahl SM. Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agents. J Clin Psychiatry. 2002 Oct; 63(10):854-5. PMID: 12416593.
      View in: PubMed
    200. Stahl SM. Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry. 2002 Sep; 63(9):756-7. PMID: 12363113.
      View in: PubMed
    201. Stahl SM, Mendels J, Schwartz GE. Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials. J Clin Psychopharmacol. 2002 Aug; 22(4):388-92. PMID: 12172338.
      View in: PubMed
    202. Stahl SM. Mirror, mirror on the wall, which enantiomer is fairest of them all? J Clin Psychiatry. 2002 Aug; 63(8):656-7. PMID: 12197444.
      View in: PubMed
    203. Stahl SM. Psychopharmacology of wakefulness: pathways and neurotransmitters. J Clin Psychiatry. 2002 Jul; 63(7):551-2. PMID: 12143908.
      View in: PubMed
    204. Stahl SM. Awakening to the psychopharmacology of sleep and arousal: novel neurotransmitters and wake-promoting drugs. J Clin Psychiatry. 2002 Jun; 63(6):467-8. PMID: 12088156.
      View in: PubMed
    205. Stahl SM. The psychopharmacology of painful physical symptoms in depression. J Clin Psychiatry. 2002 May; 63(5):382-3. PMID: 12019660.
      View in: PubMed
    206. Stahl SM. Does depression hurt? J Clin Psychiatry. 2002 Apr; 63(4):273-4. PMID: 12000200.
      View in: PubMed
    207. Stahl SM. Selective actions on sleep or anxiety by exploiting GABA-A/benzodiazepine receptor subtypes. J Clin Psychiatry. 2002 Mar; 63(3):179-80. PMID: 11926714.
      View in: PubMed
    208. Stahl SM. Antipsychotic polypharmacy: squandering precious resources? J Clin Psychiatry. 2002 Feb; 63(2):93-4. PMID: 11874226.
      View in: PubMed
    209. Stahl SM. The psychopharmacology of energy and fatigue. J Clin Psychiatry. 2002 Jan; 63(1):7-8. PMID: 11838630.
      View in: PubMed
    210. Stahl SM, Kaiser L, Roeschen J, Keppel Hesselink JM, Orazem J. Effectiveness of ipsapirone, a 5-HT-1A partial agonist, in major depressive disorder: support for the role of 5-HT-1A receptors in the mechanism of action of serotonergic antidepressants. Int J Neuropsychopharmacol. 1998 Jul; 1(1):11-18. PMID: 11281940.
      View in: PubMed
    211. Lerer B, Frazer A, Stahl S, Farde L, Lesch P. The International Journal of Neuropsychopharmacology. Int J Neuropsychopharmacol. 1998 Jul; 1(1):1-2. PMID: 11343572.
      View in: PubMed
    Stephen's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _